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Background: Reactivation of latent human cytomegalovirus (CMV) in patients
undergoing allogeneic stem-cell transplantation (HSCT) predisposes to several clinical
complications and is therefore a major cause of morbidity and mortality. Although
pentraxin-3 (PTX3) has been previously described to bind both human and murine CMV
and mediate several host antiviral mechanisms, whether genetic variation in the PTX3
locus influences the risk of CMV infection is currently unknown.
Methods: To dissect the contribution of genetic variation within PTX3
to the development of CMV infection, we analyzed described loss-of-function variants at
the PTX3 locus in 394 recipients of HSCT and their corresponding donors and assessed
the associated risk of CMV reactivation.
Results: We report that the donor, but not recipient, h2/h2 haplotype in PTX3 increased
the risk of CMV reactivation after 24 months following transplantation, with a significant
effect on survival. Among recipients with h2/h2 donors, CMV seropositive patients as well
as those receiving grafts from unrelated donors, regardless of the CMV serostatus, were
more prone to develop viral reactivation after transplantation. Most importantly, the h2/h2
haplotype was demonstrated to display an influence toward risk of CMV reactivation
comparable to that conferred by the unrelated status of the donor alone.
Conclusions: Our findings demonstrate the important contribution of genetic variation
in donor PTX3 to the risk of CMV reactivation in patients undergoing HSCT, highlighting
a promising prognostic value of donor PTX3 to predict risk of CMV reactivation in this
clinical setting.
Keywords: cytomegalovirus, stem-cell transplantation, PTX3, single nucleotide polymorphism, precision
medicine, genomics
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INTRODUCTION
Human cytomegalovirus (CMV), a member of the Herpesviridae
family, is a ubiquitous opportunistic pathogen that has
intimately co-evolved with its human host and can establish
latency after clearance of the primary infection (1). CMV
asymptomatically infects the majority of the world’s population
(approximately 40–99%), with the highest seroprevalence in
developing countries, and typically only leads to disease in the
absence of an adequate cellular immunity (2). Asymptomatic
long-term virus shedding in urine and saliva secretions
usually marks the primary infection in healthy individuals (3).
Throughout complex virus-host interactions, CMV evades a
number of host pathways to enable its lifelong persistence,
during which it may replicate chronically or reactivate from
latency sporadically (4). In immunocompetent individuals,
these reactivation events are tightly controlled by the immune
system and rarely result in clinical presentation (5). However,
it is becoming increasingly apparent that CMV may be
associated with additional long-term health consequences due
to its ability to establish lifelong persistence in critically
ill patients (6, 7). Accordingly, reactivation of latent virus
following allogeneic hematopoietic stem-cell transplantation
(HSCT) has been increasingly associated with overt CMV
disease, a major cause of morbidity and mortality in these
patients. Despite important efforts centered in diagnostic and
therapeutic advances, pre-emptive antiviral therapy is associated
with significant myelotoxicity and impaired hematological
reconstitution (8, 9), ultimately leading to other disease
complications including superinfection by other viruses, bacteria
and fungi, particularly Aspergillus species (10, 11).
The immune control of viral infections requires different
components originating from both innate and adaptive arms
of the immune system (12). Specifically, the innate immune
system has evolved a multitude of unique antiviral humoral
mechanisms through the participation of collectins, including
surfactant protein (SP)-A and SP-D, and pentraxins (13–15).
The long pentraxin-3 (PTX3) is a member of a superfamily of
fluid-phase proteins, distinguished by their cyclic multimeric
structure and the presence of a conserved amino acid
signature in their C-terminal domain (16). In response to
proinflammatory stimuli, PTX3 production is induced in a broad
range of immune cells, including macrophages, dendritic cells
and endothelial cells (17). Moreover, PTX3 is stored in the
intracellular granules of neutrophils in a ready-made form and
is rapidly released upon pathogen challenge or tissue damage,
thereby covering a temporal window preceding PTX3 gene
expression-dependent production. By acting as an ancestor
of antibodies, PTX3 exerts a multifaceted nonredundant role
in innate immunity against certain microbes by modulating
complement activity and facilitating pathogen recognition by
myeloid innate immune cells (18–20). As such, and although
classic immunodeficiencies have not been linked to PTX3
deficiency (21), common polymorphisms have been disclosed
as important risk factors across different infectious diseases,
namely Pseudomonas aeruginosa colonization in cystic fibrosis
patients (22), uropathogenic Escherichia coli infection (23), and
invasive aspergillosis in recipients of HSCT (24, 25) and solid
organ transplantation (26, 27), as well as patients with chronic
obstructive pulmonary disease (28).
Despite a well-recognized role in innate host defense against
selected bacteria and fungi, accumulating evidence also suggests
the involvement of PTX3 in innate antiviral immunity (29). In
fact, PTX3 has been described to act as a receptor decoy for the
virus during CMV infection (30). Specifically, PTX3 was found
to exert a protective role by binding both human and murine
CMV, resulting in a reduced viral entry into permissive cells and
resistance to Aspergillus superinfection, a mechanism entirely
dependent on Toll-like receptors (TLRs) sensing pathways and
activation of interferon (IFN) regulatory factor 3 (IRF3). Of note,
the exogenous administration of PTX3 resulted in therapeutic
efficacy against primary CMV infection and reactivation as
well as Aspergillus superinfection in pre-clinical models of
HSCT.
The compelling evidence that PTX3 is an effective mediator
in preventing CMV infection and reactivation as well as
subsequent superinfections pinpoints a potential role for PTX3
as a biomarker and therapeutic agent in viral infections and
superinfections in the transplantation setting. However, the
potential involvement of genetic variation in PTX3 during CMV
reactivation in at-high risk individuals has never been addressed.
In this large genetic association study involving 394 eligible
donor-recipient HSCT pairs, we provide crucial insights into
the genetic contribution of PTX3 as a critical regulator of
susceptibility to CMV infection. This informationmay ultimately
lay the foundations toward risk stratification approaches aimed at
a more effective and personalized management of CMV infection
in this clinical setting.
MATERIALS AND METHODS
Patients
A total of 460 hematological patients of European descent
undergoing allogeneic HSCT at Instituto Português de
Oncologia, Porto, and at Hospital de Santa Maria, Lisbon,
between 2009 and 2015, were enrolled. Both donor and recipient
DNA samples as well as patient-level data were available for
394 of these. The demographic and clinical characteristics of
the patients are summarized in Table 1. One hundred and
ninety-six cases of CMV infection and 198 uninfected controls
were identified through pp65/pUL83 antigenemia assay (>1/100
pp65/pUL83 antigen-positive cells) and blood quantitative PCR
for detection of viral DNA (>400 copies/mL) according to the
recent revised standard criteria (31). All patients were monitored
weekly for viral infection (reactivation or primary infection)
with CMV until day +90 post-HSCT and subsequently every
second week. In the event of increasing viral loads, pre-emptive
therapy with valganciclovir was initiated. Approval for the
study was obtained from the Ethics Subcommittee for Life and
Health Sciences of the University of Minho, Portugal (125/014),
the Ethics Committee for Health of the Instituto Português de
Oncologia, Porto, Portugal (26/015), the Ethics Committee of
the Lisbon Academic Medical Center, Portugal (632/014), and
the National Commission for the Protection of Data, Portugal
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AGE AT TRANSPLANTATION, NO (%)
≤20 years 75 (19.1) 42 (21.2) 33 (16.8) 0.37
21–40 years 103 (26.1) 54 (27.3) 49 (25.0)
>40 years 216 (54.8) 102 (51.5) 114 (58.2)
GENDER, NO (%)
Female 169 (42.9) 90 (45.5) 79 (40.3) 0.29
Male 225 (57.1) 108 (54.5) 117 (59.7)
UNDERLYING DISEASE, NO. (%)
Acute leukemia 213 (54.1) 109 (55.1) 104 (53.1) 0.79
Chronic lymphoproliferative
diseases
65 (16.5) 28 (14.1) 37 (18.9)
Chronic myeloproliferative diseases 25 (6.3) 14 (7.1) 11 (5.6)
Myelodysplastic/myeloproliferative
diseases
57 (14.5) 28 (14.1) 29 (14.8)
Aplastic anemia 19 (4.8) 10 (5.1) 9 (4.6)
Others or unknown 15 (3.8) 9 (4.5) 6 (3.1)
TRANSPLANTATION TYPE, NO. (%)
Matched, related 180 (45.7) 106 (53.6) 74 (37.8) 0.009
Matched, unrelated 106 (26.9) 43 (21.7) 63 (32.1)
Mismatched, related 6 (1.5) 4 (2.0) 2 (1.0)
Mismatched, unrelated 102 (25.9) 45 (22.7) 57 (29.1)
GRAFT SOURCE, NO. (%)
Peripheral blood 324 (82.2) 166 (83.8) 158 (80.6) 0.10
Bone-marrow 62 (15.7) 31 (15.7) 31 (15.8)
Cord blood 8 (2.0) 1 (0.5) 7 (3.6)
DISEASE STAGE, NO. (%)
First complete remission 219 (55.6) 120 (60.6) 99 (50.5) 0.13
Second or subsequent remission,
or relapse
69 (17.5) 30 (15.2) 39 (19.9)
Active disease 106 (26.9) 48 (24.2) 58 (29.6)
CONDITIONING REGIMEN, NO (%)
RIC 274 (69.5) 136 (68.7) 138 (70.4) 0.70
Myeloablative 120 (30.5) 62 (31.3) 58 (29.6)
CMV SEROSTATUS OF DONOR AND RECIPIENT, NO. (%)
D+/R+ 270 (68.5) 133 (67.2) 137 (69.9) <0.0001
D–/R+ 81 (20.6) 30 (15.2) 51 (26.0)
D+/R– 23 (5.8) 18 (9.1) 5 (2.6)
D–/R– 20 (5.1) 17 (8.6) 3 (1.5)
DURATION OF NEUTROPENIA, MEAN DAYS (RANGE)
‡
14 (5–39) 14 (6–39) 13 (5–35) 0.40
ACUTE GVHD, NO. (%)
No GVHD or grades I–II 329 (83.5) 171 (86.4) 158 (80.6) 0.12
Grades III–IV 65 (16.5) 27 (13.6) 38 (19.4)
†P-values were calculated by Fisher’s exact probability t-test or Student’s t-test
for continuous variables, comparing the groups with and without CMV infection.
‡Neutropenia was defined as ≤0.5 × 109 cells/L. RIC, reduced intensity conditioning;
CMV, cytomegalovirus; D, donor; R, recipient; GVHD, graft-vs.-host-disease.
(1950/015). All participants provided written informed consent
prior to transplantation in accordance with the Declaration of
Helsinki.
Single Nucleotide Polymorphism (SNP)
Selection and Genotyping
Genetic variants in the PTX3 gene analyzed in this study were
selected based on their described functional consequences
and previous association with infectious complications after
HSCT (24). Genomic DNA was isolated from whole blood
using the QIAmp DNA Blood Mini Kit according to the
protocol supplied by the manufacturer (Qiagen, Hilden,
Germany). Genotyping was performed using KASPar assays
(LGC Genomics, Hertfordshire, United Kingdom) in an Applied
Biosystem 7500 Fast Real-Time PCR system (Thermo Fisher
Scientific, MA, United States), according to the manufacturer’s
instructions. Mean call rate for the SNP was >98%. Quality
control for the genotyping results was achieved with
negative controls and randomly selected samples with known
genotypes.
Statistical Analysis
The probability of CMV reactivation according to PTX3
genotypes was determined using the cumulative incidence
method and compared using the Gray’s test (32). The cumulative
incidence of CMV reactivation at 24 months after HSCT was
computed with the cmprsk package for R version 2.10.1, with
censoring of data at the date of last follow-up visit and relapse
and death as competing events. All clinical and genetic variants
achieving a P ≤ 0.15 in the univariate analysis were entered
one by one in a pairwise model together and kept in the final
model if they remained significant (P < 0.05). Multivariate
analysis was performed using the subdistribution regression
model of Fine and Gray. Overall survival, defined as the time
from transplantation to death from any cause, was estimated with
the use of the Kaplan-Meier method and evaluated according
to PTX3 genotypes with the use of the log-rank test. Power
calculations were performed using the powerSurvEpi package
0.0.9 for R. Our sample size provided 80% power and a type
I error below 5% for genetic variants with allele frequencies
between 0.15 and 0.20 conferring a relative risk of 2.0.
RESULTS
Genetic Variation in PTX3 Increases the
Risk of CMV Reactivation After HSCT
The baseline demographic and transplantation characteristics
of the enrolled HSCT patients are depicted in Table 1.
No significant differences were observed among cases of
CMV reactivation and control groups regarding the age at
transplantation, gender, underlying hematological disease, graft
source, disease stage at transplantation, conditioning regimen,
development of acute graft-vs.-host disease (GVHD) and
duration of neutropenia. However, an increased number of
cases of CMV infection was detected among serologically
positive recipients (R+), whereas recipients with negative
CMV serostatus (R–) were instead more protected from viral
reactivation (P < 0.0001). In addition, HSCT patients receiving
grafts from unrelated donors were more prone to develop CMV
infection, compared to those with related donors (P = 0.009).
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To investigate the relationship between genetic variation in
PTX3 and the susceptibility to CMV reactivation, the cumulative
incidence of infection among transplant recipients was assessed
according to recipient or donor genotypes at 24 months after
HSCT. We found that donor, but not recipient, SNPs influenced
the risk of CMV reactivation (Table 2). The cumulative incidence
of CMV infection for donor rs2305619 was 59% for GG, 38%
for AG and 36% for AA (P = 0.01), whereas for rs3816527,
cumulative incidence of CMV infection was 55% for AA, 32% for
AC and 37% for CC (P = 0.03). Haplotype analysis comprising
rs2305619 and rs3816527 revealed that cumulative incidence of
infection among patients with G-A/G-A [referred to as h2/h2
(24)] donors was 63% (P = 0.008) compared to 44 and 38%
incidence observed for A-C/G-A (h1/h2) (P= 0.42) andA-C/A-C
(h1/h1) donors, respectively (Figure 1A). In accordance with the
results obtained for the individual SNPs, no significant influence
of recipient haplotypes was observed on viral reactivation, with
the cumulative incidence being 55% for h1/h1 (reference), 41%
for h1/h2 (P = 0.07) and 50% for h2/h2 (P = 0.48). Other
haplotypes were rare and were not included in the analysis (data
not shown). The key contribution of the h2/h2 haplotype to the
TABLE 2 | Cumulative incidence of CMV reactivation according to recipient and
donor PTX3 genotypes, and association test results.
RefSNP Genotype(s) Cumulative incidence of CMV
reactivation at 24 Mo (%)
Recipient P-value Donor P-value
rs2305619 AA 52 0.12 36 0.01
AG 38 38
GG 49 59
rs3816527 AA 51 0.20 55 0.03
AC 35 32
CC 52 37
CMV, cytomegalovirus; SNP, single nucleotide polymorphism; Mo, months. The P-values
are for Gray’s test using cumulative incidence analysis.
risk of infection was further illustrated uponmodeling a recessive
mode of inheritance (cumulative incidence of CMV reactivation,
63% for h2/h2 vs. 42% for h1/h1 and h1/h2 haplotypes combined;
P = 0.004) (Figure 1B).
In a multivariate model accounting for age, gender, donor
relation and CMV serostatus, the donor h2/h2 haplotype was
found to confer a 1.9-fold (95% confidence interval, 1.2–
2.9; P = 0.004) increased risk of CMV reactivation after
transplantation (Table 3). In addition, receiving grafts from
either matched (P = 0.005) or mismatched (P = 0.004)
unrelated donors also increased risk of infection, whereas CMV
seronegative recipients displayed instead a decreased risk of
infection (P = 0.01). Collectively, our results identify genetic
variation in donor PTX3 as a potentially critical risk factor
influencing the susceptibility to CMV reactivation after HSCT.
The H2/H2 Haplotype Predisposes to CMV
Infection Regardless of Viral Serostatus
and Type of Donor
Several studies have demonstrated that CMV seropositive
patients retain a higher associated mortality in comparison with
seronegative recipients who were transplanted from seronegative
TABLE 3 | Multivariate analysis of the association of PTX3 SNPs with the risk of
CMV reactivation among transplant recipients.
Genetic/clinical variables Adjusted HR† (95% CI) P-value
Donor h2/h2 haplotype in PTX3 1.9 (1.2–2.9) 0.004
Matched unrelated donor 1.9 (1.2–3.0) 0.005
Mismatched unrelated donor 1.7 (1.2–2.5) 0.004
D+/R– 0.26 (0.09–0.74) 0.01
HR, hazard ratio; CI, confidence interval. Multivariate analyses were based on the
subdistribution regression model of Fine and Gray. †Hazard ratios were adjusted
for patient age and gender, type of transplantation, graft source, disease stage at
transplantation, CMV serostatus of donor and recipient, and duration of neutropenia. Only
the variables remaining significant after adjustment are shown.
FIGURE 1 | Genetic variation in donor PTX3 increases the risk of CMV reactivation after HSCT. Genetic association study comprising 394 eligible HSCT recipients
with available clinical data and corresponding donors. (A) Cumulative incidence of CMV reactivation after HSCT according to recipient and donor haplotypes in PTX3.
(B) Cumulative incidence of CMV reactivation after HSCT according to donor haplotypes in PTX3 following a recessive genetic model. Data were censored at 24
months, and relapse and death were considered competing events. P-values were calculated using Gray’s test.
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donors (33, 34). In light of our genetic data disclosing the h2/h2
haplotype as a critical risk factor for CMV reactivation after
HSCT, we further stratified patients according to the recipient
CMV serostatus. We observed that CMV seropositive patients
(R+) carrying the risk-conferring haplotype in PTX3 displayed
the highest risk of CMV reactivation after HSCT (Figure 2A).
Specifically, the cumulative incidence of CMV reactivation
was 68% for R+ and h2/h2 (P < 0.001), 44% for R+ and
h1/h1+h1/h2 (P = 0.03), 30% for R– and h2/h2 (P = 0.20),
and 14% for R– and h1/h1+h1/h2 (reference) (Figure 2A).
These results indicate that the h2/h2 haplotype promoted a
further increased risk of CMV reactivation among both CMV
seropositive and seronegative recipients.
FIGURE 2 | Recipient serostatus and donor relation synergize with genetic
variation in PTX3 toward risk of CMV reactivation. Genetic association study
comprising 394 eligible HSCT recipients with available clinical data and
corresponding donors. Cumulative incidence of CMV reactivation after HSCT
according to donor haplotypes in PTX3 in combination with (A) recipient
serostatus (negative, R–, or positive, R+) or (B) type of donor (related, Rel, or
NRel, unrelated). Data were censored at 24 months, and relapse and death
were considered competing events. P-values were calculated using Gray’s
test.
Given that the type of donor is also a well-described pre-
transplantation predictive factor for CMV reactivation (35), we
analyzed our genetic results according to the type of donor
(related, Rel, and unrelated, NRel). We found that recipients
harboring the h2/h2 haplotype were at higher risk of CMV
infection following HSCT, regardless of the type of transplant
(Figure 2B). The cumulative incidence of viral reactivation was
66.7% for NRel and h2/h2 (P < 0.001), 56.3% for Rel and
h2/h2 (P = 0.01), 44.4% for NRel and h1/h1+h1/h2 (P = 0.02),
and 33% for Rel and h1/h1+h1/h2 (reference). Of note, the
similar incidence of CMV reactivation observed in recipients
transplanted from Rel and h2/h2 donors and those transplanted
fromNRel and h1/h1+h1/h2 donors support a comparable effect
of genetic variation in PTX3 and the type of donor toward CMV
reactivation. Collectively, these results suggest that PTX3 may
constitute an ideal candidate for antiviral prophylactic measures
aimed at counteracting the onset of CMV reactivation in HSCT
patients.
The H2/H2 Haplotype Influences
Post-transplant Mortality
In view of our findings highlighting the genetic variation
in PTX3 as promising predictive clinical candidate for CMV
reactivation in HSCT patients, we next sought to investigate
whether the donor h2/h2 haplotype influenced post-transplant
mortality. The probability of overall survival was evaluated at
36 months following transplantation and estimated according
to donor PTX3 haplotypes. We observed that, consistent with
the increased risk of CMV reactivation, the donor h2/h2
haplotype influenced the post-transplant survival of HSCT
patients (Figure 3). The probability of survival decreased from
54% among patients who received transplants from either
h1/h1 or h1/h2 donors to 45% among patients who received
transplants from donors carrying the risk-conferring h2/h2
haplotype (P = 0.04). Taken together, these results highlight
the potential role of genetic variation in PTX3 as an important
predictor of the risk of infection, but also the outcome of the
patients.
FIGURE 3 | The donor h2/h2 haplotype in PTX3 influences post-transplant
survival of HSCT recipients. Overall survival (OS) according to donor
haplotypes in PTX3. Data were censored at 36 months. P-values were
calculated using the log-rank test.
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DISCUSSION
Although remarkable advances in molecular virology and
improvements in diagnostic methods and treatment regimen
options have vastly enhanced our ability to manage CMV
infection (36, 37), reactivation of latent virus remains one
major cause of morbidity and mortality in patients undergoing
HSCT (11). There is therefore a pressing demand for the
development of novel prognostic markers for CMV reactivation
aimed at supporting risk stratification measures and early
diagnosis of infection. In this regard, the rs12979860 SNP
upstream of the IL28B gene, known to be a critical factor
associated with spontaneous clearance of hepatitis C (38), has
been reported to influence the risk of CMV infection through
the regulation of CMV-specific T-cell responses (39). Another
study, despite failing to detect association, also revealed a
contribution of the same IL28B variant to the levels of CMV
DNAemia (40). In addition, SNPs in innate immunity genes,
most notably TLR9 (41, 42), also appear to be important
repositories of variability toward CMV infection across different
studies. Collectively, these findings point to a strong genetic
component in defining susceptibility to CMV reactivation after
HSCT.
In this study, we have disclosed genetic variation in PTX3
as an independent prognostic factor for CMV reactivation
after transplantation, providing additional insights into human
susceptibility to CMV infection. In addition, we determined a
significant contribution of the donor h2/h2 haplotype to a poorer
survival of HSCT recipients, similar to that previously reported
among recipients of grafts from HLA-mismatched donors (24).
This may reflect a key role of the h2/h2 haplotype in defining the
outcome of HSCT patients by enhancing the risk of infectious
complications. It remains to be assessed whether these genetic
variants may also affect other non-infectious complications
associated withHSCT. In this regard, it is worthwhile mentioning
that plasma levels of PTX3 were increased at the onset
of GVHD and were predictive of disease outcome (43),
although the potential contribution of genetic variation in
PTX3 to the risk and progression of GVHD remains to be
assessed.
The integration of genetic markers into clinically valid
processes to stratify the risk and progression of viral infection,
and the efficacy of antiviral prophylaxis and therapy may
represent a groundbreaking innovation for at-risk patients. In
addition, the mechanistic involvement of PTX3 during CMV
infection has been known for a long time (17, 44). By binding to
CMV through sialic acids expressed on its glyosidicmoiety, PTX3
was demonstrated to be effective in averting CMV infection and
reactivation in selected in vivo and in vitro models of infection
(30). Our genetic study associating a loss-of-function haplotype
with the risk of CMV reactivation further supports the previously
reported antiviral role of PTX3 and, considering its therapeutic
potential in pre-clinical models (30), the administration of
PTX3 could be envisaged as a promising immunotherapeutic
approach to rescue the genetic deficiency in at-risk
patients.
Although major advances have been accomplished regarding
antiviral prophylactic strategies and preemptive therapy (9, 45),
the donor and recipient CMV serological status still plays
a major influence on the outcome of post-transplantation
complications (46). Numerous investigations have demonstrated
that CMV seronegative recipients transplanted from equally
seronegative donors retain a reduced risk of transplant-related
mortality, especially that caused by infections, in comparison
with serologically positive recipients (47, 48). In line with
the reported data, we found a significantly increased number
of CMV reactivation cases among seropositive patients. Most
importantly, our observation that R+ and h2/h2 recipients
were at the highest risk of CMV reactivation highlights PTX3
as an ideal candidate for personalized medical interventions
such as intensified diagnostics and targeted preemptive antiviral
prophylaxis to prevent and counteract the onset of infection
in specific subgroups of patients that are most at risk of viral
reactivation.
Within the criteria for donor selection, the relation between
donor and recipient constitutes one of the most relevant
pre-transplantation predictors of CMV reactivation after
transplantation (35, 49). In accordance, we found a significantly
increased number of cases of CMV reactivation among patients
with unrelated donors. Since the success of transplantation
procedures hinges on the availability of suitable donors (50),
our results suggest a pivotal role for PTX3 genetics as a
pre-transplantation factor that could reshape current clinical
approaches through the implementation of innovative risk
stratification strategies that may involve the choice of alternative
donors. Indeed, our results appear to indicate that selection
of donors carrying the h2/h2 haplotype in PTX3 may have a
detrimental effect toward the reactivation of CMV after HSCT
comparable to that conferred by the unrelated status of the donor
alone.
Given its exploratory nature, our study presents certain
limitations. The most important refer to the absence of definitive
conclusions about the mechanism(s) through which genetic
variation in donor PTX3 influences the risk of developing CMV
infection. Although it could presumably involve the transfer of
CMV-specific lymphocytes, this hypothesis needs to be further
explored. In addition, the low number of cases of overt CMV
disease in our cohort precluded the appreciation of potential
associations between severe viral disease and genetic variation in
PTX3. Functional studies are ultimately required to understand
how PTX3 is regulated in response and during CMV infection
after HSCT, and what is the relative involvement of genetic
variation in defining the levels of PTX3 and contributing to
infection.
In conclusion, the evidence presented herein for a robust
association between genetic variation in PTX3 and CMV
reactivation in patients undergoing HSCT highlights the
significance of PTX3 as a promising marker for personalized
medical intervention strategies, especially in the HSCT
population, which may be particularly well-suited for
genetically-targeted antiviral prophylaxis or enhanced diagnostic
surveillance (51).
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